Paper Details

  1. Home
  2. Paper Details

Intermittent high-dose melphalan/prednisone vs continuous low-dose melphalan treatment in multiple myeloma.

Author: AhreA, BjörkholmM, BrenningG, EngstedtL, GahrtonG, HolmG, HällenJ, JohanssonB, JohanssonS G, KarnströmL, KillanderA, LernerR, LocknerD, LönnqvistB, MellstedtH, SimonssonB, StalfeltA M, TernstedtB, WadmanB

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A study of 219 patients with newly diagnosed multiple myeloma found that intermittent high-dose melphalan/prednisone therapy was more effective than continuous low-dose melphalan therapy in achieving remission and improving survival, especially for stage I and II myeloma.
Paper Details　
Original Abstract of the Article :
Patients with newly diagnosed multiple myeloma were randomly allotted to an intermittent high-dose melphalan/prednisone (MP) treatment (120 patients) or a continuous low-dose melphalan (M) regimen (99 patients). The median observation time was 59 months (range 33-84). Response to therapy was obtaine...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/0277-5379(83)90113-x

データ提供：米国国立医学図書館（NLM）

Intermittent High-Dose Melphalan/Prednisone vs. Continuous Low-Dose Melphalan Treatment in Multiple Myeloma

The vast and mysterious desert of multiple myeloma research is always beckoning us to uncover new truths. This study, like a tireless camel traversing the sands, explores a crucial question: is intermittent high-dose therapy better than continuous low-dose therapy for treating multiple myeloma? The researchers, armed with the tools of randomization and observation, embarked on a journey to find answers. They divided patients with newly diagnosed multiple myeloma into two groups, one receiving intermittent high-dose melphalan/prednisone (MP) and the other receiving continuous low-dose melphalan (M). Their findings, like shimmering oases in the desert, revealed a statistically significant difference in response to therapy, with the MP group showing a higher response rate. This suggests that intermittent high-dose therapy might hold the key to a more effective treatment strategy.

The Potential of Intermittent High-Dose Therapy

The results of this study indicate that intermittent high-dose melphalan/prednisone therapy might be a more effective treatment for multiple myeloma compared to continuous low-dose melphalan therapy. The MP group showed a significantly higher response rate (45% vs. 31%), indicating that the intermittent high-dose approach could lead to better outcomes for patients.

Implications for Patients and Future Research

This research provides valuable insights into the potential benefits of intermittent high-dose therapy for multiple myeloma. However, it is crucial to remember that this is just one study and more research is needed to confirm these findings and understand the long-term effects of this treatment approach. As we continue our explorations in the desert of myeloma research, we must remain vigilant and open to new discoveries that could improve the lives of patients suffering from this challenging disease.

Dr.Camel's Conclusion

Just as a camel adapts to the harsh desert environment, patients with multiple myeloma need treatment strategies that are tailored to their individual needs. This study suggests that intermittent high-dose therapy could be a promising option, but more research is needed to understand its full potential and determine its optimal use in various clinical settings.

Date :
  1. Date Completed 1983-08-17
  2. Date Revised 2019-09-08
Further Info :

Pubmed ID

6345174

DOI: Digital Object Identifier

10.1016/0277-5379(83)90113-x

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.